📰 Amy Wolf News
Page 7 - Amy Wolf News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Amy Wolf. Real-time updates on events, politics, business and more.
June 21, 2022
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod) dosing regimen patent
June 21, 2022
Ad hoc announcement pursuant to Art. 53 LR Basel, June 21, 2021 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit issued a new, negative decision regarding... | June 21, 2022
June 12, 2022
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL
June 12, 2022
In final ELIANA analysis, 55% of patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (ALL) who were treated with CAR-T cell therapy Kymriah were still alive after five years1 Nearly
June 7, 2022
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial
June 7, 2022
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif* (bosutinib) at 96 weeks (37.6% vs. 15.8%), building on 24-week
May 27, 2022
68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable safety profile1 Sustained clinical benefit from Kymriah
May 27, 2022
Investegate announcements from NOVARTIS AG CHF0.50(REGD), FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
May 12, 2022
Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new biomarker
May 12, 2022
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer